DSCO

[nica33]

In my watchlist for tomorrow.  Nice steady trend.  Bullish candle.

[akclide]

DSCO is gaining ground every day for the past few days. Today movement includes volume.Drug may ne coming to the market soon.

[setravis]

Here is Today's closing chart....... Good speculation !
From what I can read, this stock has good
potential to move past $5.00

52wk Range: 1.16 - 3.21
Volume: 4,324,290
Avg Vol (3m): 623,619

Technicals
Record Price High
Record Price Break Out
Percentage Gainer

Last Price Quote is:
23.02%above 13-day MA
35.83%above 50-day MA
RS Rating: 94 

Fundamentals
Earnings Expected on May 8

Key Data:
Market Cap (M): $203.75 
P/E Ratio: NA 
PEG Ratio: N/A 
Next Earnings: 05/08/2007
Last Analyst Rating: Buy

[setravis]

(DSCO).......
ANNOUNCES FDA ACCEPTANCE OF SUBMISSION: Discovery Laboratories, Inc. (DSCO)
announced that the FDA has accepted Discovery Labs' submission of November 1, 2007 as
a complete response to the April 2006 Approvable Letter for Surfaxin(R) (lucinactant), for the
prevention of Respiratory Distress Syndrome (RDS) in premature infants. The FDA has established
May 1, 2008 as its target date to complete its review of the Surfaxin New Drug Application
(NDA).



Friday's closing chart.
Double Bottom.......Maybe ?

[setravis]

ANNOUNCES $25M PRIVATE PLACEMENT: Discovery Laboratories, Inc. (DSCO) has obtained
commitments to raise $25.0 million, before deducting placement agents' fees and offering
expenses, in a registered direct offering. Discovery Labs will sell 10,000,000 shares of its
common stock to a select group of institutional investors at a purchase price of $2.50 per share.
The closing of the offering is expected to take place on December 12, 2007, subject to the satisfaction of customary closing conditions. All of the shares of common stock are being offered
by Discovery Labs.

[setravis]

▼TOP NEWS LOSERS


RECEIVES APPROVABLE LETTER FROM FDA: Discovery Laboratories, Inc. (DSCO) announced
that it has received an Approval Letter from the FDA for Surfaxin(R) (lucinactant) for
the prevention of Respiratory Distress Syndrome (RDS) in premature infants. Discovery Labs
is assessing the Approval Letter and will contact the FDA within the next few days to discuss
required actions and timing to gain Surfaxin approval. Discovery Labs expects to be in a position
early next week to provide guidance regarding its plans and timeline considerations to address
the Approval Letter.

[la-onda]

DSCO: Short Interest UP 8.7% to 8.2M at the End of May 2008
Wednesday, June 11, 2008 06:00ET

According to new short interest data from NASDAQ, short interest for Discovery Laboratories Inc (NasdaqNM: DSCO) INCREASED 8.7% to 8,237,865 shares as reported at month-end May, 2008.
Based on DSCO's 20-day average daily share volume of 934,865, it would require approximately 9 day(s) of buying to cover this short interest.


DSCO: Volume Spike; 43% > 20-adsv, Stock +2.55%
Wednesday, June 11, 2008 14:05ET

This is the 1st VOLUME alert for DSCO in the past 7 calendar days.

Trading for Discovery Laboratories Inc (NASDAQ NM: DSCO) has been heavier than usual in today's session. By 14:05 ET, the stock had already traded 1,320,019 shares via 2,697 trades. The cumulative volume is 42.56% above its 20-day average of 925,965. Normally the stock experiences around 1,828 individual trades per session.

So far, today's volume surge has caused a net rise in DSCO's stock price. At the time of this alert, the stock was trading at $1.979, up $0.049 (+2.55%).

One year ago, the Company's shares closed at $3.190. The price has declined more than 37 percent since then.

Over the last 10 trading session DSCO has traded in a range between $1.740 and $1.950 and is currently trading 44.71% below its 52-week high of $3.580 set on June 20,2007 and 53.43% above its 52-week low of $1.290 from May 02,2008.

In the previous 3 sessions, DSCO trading has displayed a mixed trend. Closing results have been as follows:

June 10, 2008 --- closed at $1.930 up $0.120 (+6.63%) on 985,000 shares
June 09, 2008 --- closed at $1.810 down $0.040 (-2.16%) on 841,400 shares
June 06, 2008 --- closed at $1.850 even for the day on 726,900 shares

The Company last released news on May 29, 2008:

"Discovery Labs and FDA to Meet On June 18, 2008 to Clarify Limited Items in SURFAXIN Approvable Letter"

[setravis]

Spec play. (Long Recommendation)
Stop $1.15. Speculation play. Also, CEO bought 40K shares in Nov.
Insider buying.
Discovery Labs CEO bought 40k shares at $1.01 on 11/17 


From Mike Havrilla on Seeking Alpha: Last fall, Discovery Labs (DSCO) received word from the FDA that its complete response for Surfaxin was accepted, but the six-month Class II review designation means that the decision date is pushed out to mid-April. DSCO presents a model trade on a pending FDA decision at this time since it will likely enjoy a run-up in share price from current levels around $1.20 as the decision date nears. If DSCO experiences the bump in price, simply let the profits ride through the decision or just book all of the gains for a lower risk, lower reward trade on the expected increase in share price volatility heading into mid-April.

52wk Range: 0.77 - 3.02
Volume: 361,978
Avg Vol (3m): 563,088

Technicals
Close Below the 13-day MA

Last Price Quote is:
-0.17%below 13-day MA
-6.19%below 50-day MA
RS Rating: 25 

Fundamentals
Key Data:
Market Cap (M): $117.57 
P/E Ratio: NA 
PEG Ratio: N/A 
Next Earnings: 02/05/2009
Last Analyst Rating: Buy

[la-onda]

fyi:
Discovery Labs Reports Fourth Quarter 2008 Financial Results
Friday , March 13, 2009 07:15ET
Discovery Laboratories

WARRINGTON, Pa., March 13, 2009 (GLOBE NEWSWIRE) -- Discovery Laboratories, Inc. (Nasdaq:DSCO) today announced financial results for the fourth quarter ended December 31, 2008.

For the quarter ended December 31, 2008, the Company reported a net loss of $8.5 million (or $0.08 per share) on 100.5 million weighted average common shares outstanding compared to a net loss of $12.0 million (or $0.14 per share) on 88.5 million weighted average common shares outstanding for the same period in 2007. Net cash burn for the fourth quarter of 2008 was $6.7 million, reflecting $7.6 million used for operating activities and $0.9 million used for debt service, offset by aggregate proceeds of $1.8 million received from the issuance of 1.4 million shares of common stock pursuant to financings under the Company's Committed Equity Financing Facilities (CEFFs).

As of December 31, 2008, the Company had cash and marketable securities of $24.8 million. Additionally, the Company has the ability (subject to certain conditions, including price and volume limitations) to raise capital under its existing CEFFs to support its business plans. As of December 31, 2008, there were approximately 15.0 million shares (not to exceed an aggregate of $25.0 million) remaining available for issuance under the December 2008 CEFF, approximately 15.6 million shares (not to exceed an aggregate of $54.9 million) under the May 2008 CEFF, and approximately 4.5 million shares under the 2006 CEFF, which will expire in May 2009. As of March 12, 2009, a maximum of $34 million is available to the Company after giving effect to applicable discounts. The Company had 101.3 million common shares outstanding as of December 31, 2008.

The decrease in net loss for the fourth quarter of 2008 as compared to the fourth quarter of 2007 is primarily due to the Company's efforts during the fourth quarter of 2008 to conserve financial resources by limiting program development activities as we await April 17, 2009, the U.S. Food and Drug Administration's (FDA) target action date to complete its review of the NDA for Surfaxin(r) (lucinactant) for the prevention of Respiratory Distress Syndrome (RDS) in premature infants. Additionally, in the fourth quarter of 2007, the Company incurred significant expenses related to the development of its Capillary Aerosolization Technology for the delivery of aerosolized KL4 Surfactant.

Robert J. Capetola, Ph.D., President and Chief Executive Officer of Discovery Labs, commented, "We believe our KL4 Surfactant and Capillary Aerosolization Technology Platform has the potential to address multiple respiratory problems in a range of patient populations from premature infants to adults. Our top priority is to gain potential FDA marketing approval for Surfaxin for the prevention of RDS in premature infants. As we await the FDA's decision, we plan to continue to conserve our financial resources while simultaneously preparing to build a significant pediatric respiratory franchise around our lead pipeline programs, Surfaxin and Aerosurf(r)."

Selected Key Priorities for 2009 include:


* We are focused on potentially gaining FDA approval for Surfaxin for
   the prevention of RDS in premature infants. The FDA has established
   April 17, 2009 as its target action date to complete its review. If
   approved, Surfaxin will represent the first synthetic,
   peptide-containing surfactant for use in pediatric medicine and the
   first product from our technology platform. 

* Initiate our Phase 2 clinical program for Aerosurf(r), our
   proprietary KL4 Surfactant in aerosolized form, which we are
   developing using our Capillary Aerosolization Technology, initially
   for premature infants at risk for RDS.  Aerosurf will potentially
   provide the neonatal medical community, for the first time, an
   ability to treat premature infants at risk for RDS without the
   risks generally associated with invasive endotracheal intubation
   and mechanical ventilation.  We believe that Aerosurf holds the
   promise to significantly expand the use of surfactants in pediatric
   medicine.

* Advance our ongoing Phase 2 trial of Surfaxin for children up to 2
   years of age with Acute Respiratory Failure, continue our support
   of a sponsor initiated Phase 2a trial at University of North
   Carolina that is using our aerosolized KL4 surfactant in patients
   with Cystic Fibrosis, and continue development of our novel
   lyophilized KL4 Surfactant, Surfaxin LS, which is manufactured in a
   dry powder form and reconstituted as a liquid just prior to
   administration. Surfaxin LS, among other things, may potentially
   simplify storage requirements and methods of administering
   surfactant.

* Following the potential approval of Surfaxin, we plan to establish
   our own specialty pulmonary commercial organization that will focus
   on creating a significant presence in the neonatal and pediatric
   intensive care units. Alternatively, we would also consider a
   strategic alliance or collaboration, assuming such a potential
   transaction would meet our business and strategic requirements. 

* Secure strategic alliances to strengthen our financial position,
   support development and commercialization of our pediatric
   respiratory franchise in international markets and support
   development and commercialization of our adult respiratory programs
   in worldwide markets.

Readers are referred to, and encouraged to read in its entirety, the Company's Annual Report on Form 10-K for the fiscal year ended December 31, 2008, which includes full details on the Company's business plans and operations, financial condition and results of operations. The Company's audited financial statements for the year ending December 31, 2008, are accompanied by an unqualified audit opinion from Ernst & Young LLP, the Company's independent public accounting firm, which includes a "going concern" explanatory statement. The Company is providing this information to comply with Nasdaq Marketplace Rule 4350(b)(1)(B), which requires an issuer that receives an audit report containing a going concern explanatory statement to make a public announcement through the news media disclosing the receipt of such statement.

&

Discovery Labs Advances KL4 Surfactant Technology Platform With Lyophilized Formulation
Thursday , March 26, 2009 07:00ET
Discovery Laboratories

WARRINGTON, Pa., March 26, 2009 (GLOBE NEWSWIRE) -- Discovery Laboratories, Inc. (Nasdaq:DSCO) today announces that it has created a lyophilized formulation of its synthetic, peptide-containing KL4 surfactant technology. Lyophilized KL4 surfactant is being developed to support Discovery Labs' pipeline of surfactant product candidates including Surfaxin(r) (lucinactant as a liquid formulation) and Aerosurf(r) (lucinactant as an aerosolized formulation). Discovery Labs is developing a pipeline of surfactant-based therapies targeted to address several respiratory disorders associated with surfactant deficiency or dysfunction. Lyophilized KL4 surfactant is manufactured as a dry powder formulation that is reconstituted prior to use. Key next steps include planned discussions with global regulatory agencies intended to determine the development pathway leading to the initiation of a late-stage neonatal clinical trial program.

The currently available surfactants are animal-derived liquid formulations that require constant refrigeration prior to use. Surfaxin, which is Discovery Labs' lead product that is currently under review by the United States FDA for potential approval for prevention of Respiratory Distress Syndrome (RDS) in premature infants, also requires refrigeration prior to use. Lyophilized KL4 surfactant is intended to eliminate continuous cold chain storage and refrigeration, greatly improving product flexibility and ease of use for healthcare practitioners. In addition, Discovery Labs believes that its lyophilized formulation has the potential to:


    * simplify drug administration with reduced preparation time,
    * improve drug product stability with extended shelf-life, and
    * further improve product clinical performance.

Robert J. Capetola, Ph.D., President and Chief Executive Officer of Discovery Labs, commented, "We have established that the key functional attributes of our liquid KL4 surfactant are preserved following lyophilization and are now completing development activities to support our regulatory and clinical development paths. A comprehensive assessment of development scale manufacturing lots is ongoing including full drug product characterization. These development lots are also actively being assessed under both real-time and accelerated stability protocols and are being evaluated in several proof-of-concept experiments in well established pre-clinical RDS models. Importantly, the results of this work may provide additional intellectual property to support our technology platform. We believe that our lyophilized KL4 surfactant technology could provide several technical advantages for our surfactant product candidates."

Discovery Labs is planning a worldwide, late-stage development program for Surfaxin LS(tm), the lyophilized formulation of Surfaxin, for the prevention of RDS in premature infants. To pursue regulatory approval for Surfaxin LS in the United States, Discovery Labs plans to request a pre-IND meeting with the FDA with a view to agreeing upon and potentially initiating a clinical trial with Surfaxin LS in 2010. Similarly, to gain regulatory approval for Surfaxin LS in Europe, Discovery Labs plans to request a scientific advice meeting with the EMEA with a view to agreeing upon and potentially initiating a clinical trial in 2010. If a similar clinical trial design satisfies both regulatory agencies, Discovery Labs anticipates conducting a single clinical program to gain regulatory approval for Surfaxin LS in the United States and Europe.

"We believe there is an unprecedented opportunity to improve the management of RDS throughout the world," commented Dr. Thomas F. Miller, Discovery Labs' Senior Vice President of Commercialization and Corporate Development. "The neonatal market is quite underserved today. We remain committed to the advancement of our KL4 surfactant technology platform to improve the quality of RDS management in the neonatal intensive care unit. Our three lead programs, Surfaxin, Surfaxin LS and Aerosurf, represent a completely new and comprehensive approach for RDS management in which the therapeutic solution is tailored to the unique need of a patient."


&


DSCO: Volume Spike; 18% > 20-adsv, Stock +8.97%
Tuesday , April 07, 2009 11:30ET

This is the 3rd VOLUME alert for DSCO in the past 7 calendar days.

Trading for Discovery Laboratories Inc (NASDAQ NM: DSCO) has been heavier than usual in today's session. By 11:30 ET, the stock had already traded 855,043 shares via 1,437 trades. The cumulative volume is 18.02% above its 20-day average of 724,485. Normally the stock experiences around 1,329 individual trades per session.

So far, today's volume surge has caused a net rise in DSCO's stock price. At the time of this alert, the stock was trading at $1.700, up $0.140 (+8.97%).

One year ago, the Company's shares closed at $2.340. The price has declined more than 27 percent since then.

Over the last 10 trading session DSCO has traded in a range between $1.170 and $1.580 and is currently trading 43.71% below its 52-week high of $3.020 set on April 29,2008 and 120.78% above its 52-week low of $0.770 from November 21,2008.

In the previous 3 sessions, DSCO trading has displayed a positive trend. Closing results have been as follows:

April 06, 2009 --- closed at $1.560 up $0.150 (+10.64%) on 2,342,700 shares
April 03, 2009 --- closed at $1.410 up $0.020 (+1.44%) on 646,000 shares
April 02, 2009 --- closed at $1.390 up $0.070 (+5.30%) on 877,600 shares

[setravis]

la-onda, Thanks for the update...Applaud 
From looking at the chart, to me a Head and Shoulders Bottom.
1 - 2 - 3 day moving averages are all moving up higher.
The relative strength index is at 74.72 which is very high.
Analyst Rating is good.
I'll check it in the morning and see where it stands.
What are stocks but hoping that you make some money at them!!!
CEO bought 40K shares in Nov. Due for FDA review for Surfaxin in mid-April.



52wk Range: 0.77 - 3.02
Volume: 931,841
Avg Vol (3m): 513,760

Technicals
Last Price Quote is:
21.48%above 13-day MA
35.09%above 50-day MA
RS Rating: 92 

Fundamentals
Key Data:
Market Cap (M): $144.60 
P/E Ratio: NA 
PEG Ratio: N/A 
Next Earnings: 05/05/2009
Last Analyst Rating: Buy